A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2
12
about 2.4 years
18–75
9 sites in CA, FL, GA +5
About this study
This trial is testing the safety and feasibility of a bone marrow transplant from a deceased donor in people with leukemia, myelodysplastic syndrome, and certain lymphomas. Participants will receive either myeloablative or reduced intensity conditioning before the transplant. They will be followed for 56 days to monitor safety and remain under follow-up for one year.
Based on ClinicalTrials.gov records.
What participants do
- 1.Ossium HPC Marrow, Bone Marrow Transplant
- 2.Post-transplant treatment
- 3.Pre-transplant conditioning - Myeloablative (MAC)
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: CTCAE Grade 3/4 Adverse Events (AEs), CTCAE Grade 3/4 Adverse Events (AEs) attributed to infusion of Ossium HPC, Marrow, Death, Serious Adverse Events
Oncology